Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Glioma × Lapatinib × Clear all

Phase

Status

Sponsor Class

NIH 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 69 Neoplasms 20 Neoplasm Metastasis 12 Brain Neoplasms 4 Stomach Neoplasms 2 Recurrence 2 Osteitis Deformans 2 Inflammatory Breast Neoplasms 2 Head and Neck Neoplasms 2 HER2 Positive Metastatic Breast Cancer 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Ovarian Neoplasms 1 HER2-positive Advanced Breast Cancer 1 HER2+ Metastatic Breast Cancer (MBC) 1 HER-2 Gene Amplification 1 Glioma 1 Glioblastoma 1 Diarrhea 1 Carcinoma 1 Breast Diseases 1 Advanced Solid Tumors 1 Adenocarcinoma 1

Interventions

Temozolomide 32 Radiotherapy 11 Bevacizumab 10 Surgical Procedures, Operative 7 IL13-PE38 7 TIC10 compound 6 Lomustine 6 Carboplatin 6 Radiation 5 Chlorotoxin 5 vorasidenib 4 trametinib 4 dabrafenib 4 Valacyclovir 4 OKN 007 4 Flucytosine 4 Dianhydrogalactitol 4 vocimagene amiretrorepvec 3 abemaciclib 3 Paclitaxel 3 Nivolumab 3 Irinotecan 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 Cyclophosphamide 3 CLR1404 3 trans-sodium crocetinate 2 pembrolizumab 2 olutasidenib 2 marizomib 2 lenvatinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00350727 2013-04-19

VEG102857

GlaxoSmithKline

Phase 2 Completed

75 enrolled 45 charts

Glioblastoma, Glioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡